- Home
- KROS vs CTO Comparison
KROS vs CTO Comparison
Compare KROS & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- CTO
- Stock Information
- Founded
- KROS 2015
- CTO 1902
- Country
- KROS United States
- CTO United States
- Employees
- KROS N/A
- CTO N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- CTO Real Estate Investment Trusts
- Sector
- KROS Health Care
- CTO Real Estate
- Exchange
- KROS Nasdaq
- CTO Nasdaq
- Market Cap
- KROS 565.0M
- CTO 569.2M
- IPO Year
- KROS 2020
- CTO N/A
- Fundamental
- Price
- KROS $15.66
- CTO $16.53
- Analyst Decision
- KROS Buy
- CTO Strong Buy
- Analyst Count
- KROS 14
- CTO 3
- Target Price
- KROS $20.56
- CTO $22.00
- AVG Volume (30 Days)
- KROS 430.7K
- CTO 238.0K
- Earning Date
- KROS 11-05-2025
- CTO 10-23-2025
- Dividend Yield
- KROS N/A
- CTO 9.20%
- EPS Growth
- KROS N/A
- CTO N/A
- EPS
- KROS 0.47
- CTO N/A
- Revenue
- KROS $232,844,000.00
- CTO $140,996,000.00
- Revenue This Year
- KROS $5,579.44
- CTO $21.72
- Revenue Next Year
- KROS N/A
- CTO $7.32
- P/E Ratio
- KROS $33.65
- CTO N/A
- Revenue Growth
- KROS 85820.30
- CTO 22.26
- 52 Week Low
- KROS $9.12
- CTO $16.12
- 52 Week High
- KROS $72.37
- CTO $20.88
- Technical
- Relative Strength Index (RSI)
- KROS 59.38
- CTO 39.69
- Support Level
- KROS $15.23
- CTO $16.42
- Resistance Level
- KROS $15.85
- CTO $17.57
- Average True Range (ATR)
- KROS 0.52
- CTO 0.24
- MACD
- KROS 0.01
- CTO -0.04
- Stochastic Oscillator
- KROS 72.91
- CTO 9.57
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.